Neuraceq, or florbetaben F18 injection, can help estimate the density of neuritic plaque in the brain for patients who are under evaluation for Alzheimer’s disease or other forms of cognitive decline, according to the news release.
If a Neuraceq scan shows little to no neuritic plaque, it indicates a lesser likelihood that the patient’s cognitive impairment is due to Alzheimer’s, according to the news release.
While the imaging agent “does not establish the diagnosis of AD or any other cognitive disorder,” it’s estimation of neuritic plaque density is a tool to help physicians determine an eventual diagnosis, according to the release.
More Articles on FDA Approvals:
FDA Approves Implantable Device for Certain Type of Hearing Loss
FDA Approves Apixaban for New Use
FDA Approves Migraine ‘Headband’ for Marketing
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
